T1	Participants 114 166	stage III colon cancer (NCCTG N0147 Clinical Trial).
T2	Participants 492 586	patients with stage III colon cancer who enrolled in a phase III clinical trial (NCCTG N0147).
T3	Participants 841 888	between patients defined by LCS6 variant status
T4	Participants 1392 1424	in Caucasians versus other races
T5	Participants 1890 1923	in patients with stage III tumors
